Assessing the BD landscape for in-licensing & acquisition deals in GI

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...
Learn More

Due diligence of a biotech with a novel single chain antibody platform

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...
Learn More

Assessment of TLR immunomodulators in oncology and HIV

Challenge: A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...
Learn More

Deal benchmarks & term sheet appraisal for an early-stage license deal

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...
Learn More

Investor due diligence of a development-stage microbiome company

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Pharmaceutical Licensing: Negotiation Support

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
Learn More

Expert evaluation of the likelihood of success of Phase III trial in CNS

Challenge: A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS...
Learn More

Due diligence of a plasma protein manufacturer for a PE investor

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...
Learn More

Developing an independent market report for a cannabinoid company seeking a dual-listing

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
Learn More

Due diligence on a new medical imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Valuation of a cancer therapy for licensing deal

Challenge: A biotech company developing small molecule drugs for oncology was in the process of licensing negotiations with a pharma company for its lead asset. The asset, set to enter the clinic in...
Learn More